• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)

AmerisourceBergen, a global healthcare solutions leader, today announced that US Bioservices, an independent specialty pharmacy, has been selected by Emmaus Medical, Inc. as the specialty pharmacy for EndariTM (L-glutamine oral powder), for the treatment of patients with sickle cell disease.

The U.S. Food and Drug Administration approved Endari on July 7, 2017 for adult and pediatric patients 5 years of age and older to reduce acute complications of sickle cell disease. Endari is the first approved treatment for sickle cell disease in pediatric patients and the first new treatment available in nearly 20 years for adults.

As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients. In addition to utilizing the comprehensive clinical services of US Bioservices, Emmaus will also collaborate with AmerisourceBergen’s ASD Healthcare and ICS.


To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.